BASF Pharma Solutions Announces Global Price Adjustment for Pharmaceutical Excipients and Selected APIs

• Price adjustment supports continued reliability and quality amid rising global energy and raw material costs.
• Excipients are inactive ingredients that play a critical role in pharmaceutical formulations. APIs are Active Pharmaceutical Ingredients.

Florham Park, New Jersey, March 30, 2026 –

BASF Pharma Solutions today announced a global price increase for excipients and selected active pharmaceutical ingredients (APIs) supplied by the company. The adjustment supports BASF’s commitment to maintaining a reliable supply of high-quality products across its portfolio amid rising global energy and raw material costs.

A price increase of up to 20% will go into immediate effect, or as existing contracts allow. BASF Pharma Solutions will continue to monitor market conditions and communicate any future adjustments as needed.

Excipients are inactive ingredients that play a critical role in pharmaceutical formulations. APIs are the active components responsible for the therapeutic effect of medicines.

About BASF
At BASF, we create chemistry for a sustainable future. Our ambition: We want to be the preferred chemical company to enable our customers’ green transformation. We combine economic success with environmental protection and social responsibility. Around 108,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises, as core businesses, the segments Chemicals, Materials, Industrial Solutions, and Nutrition & Care; our standalone businesses are bundled in the segments Surface Technologies and Agricultural Solutions. BASF generated sales of around €60 billion in 2025. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at www.basf.com.

P-26-062